| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 25g |
|
||
| 100g | |||
| Other Sizes |
| Targets |
5-Fluoroisatin has been approved by the FDA in 2006 for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). The compound's mechanism of action is related to its isatin scaffold, which can interact with various biological targets including kinases and enzymes involved in cancer cell proliferation. 5-Fluoroisatin has also shown antibacterial, antifungal, and potential antimycobacterial activities. The fluorine substituent enhances the compound's metabolic stability and binding affinity to target proteins. The compound's multiple biological activities make it valuable for drug discovery and pharmacological research.
|
|---|---|
| ln Vitro |
In vitro, 5-fluoroisatin has demonstrated antibacterial and antifungal activities. It is used as a biochemical reagent and organic compound for biomedical research. The compound's isatin scaffold allows for various chemical transformations, making it valuable for drug discovery and medicinal chemistry. Cellular assays typically evaluate its anticancer, antibacterial, or antifungal activity. The compound's ability to inhibit cancer cell proliferation and microbial growth makes it valuable for studying various disease mechanisms. The compound's FDA approval for cancer treatment is based on its in vivo efficacy.
|
| ln Vivo |
In vivo, 5-fluoroisatin has been approved by the FDA for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). The compound's efficacy in these indications has been established through clinical trials. The compound's mechanism of action involves inhibition of cancer cell proliferation and induction of apoptosis. Its fluorine substituent enhances its metabolic stability and bioavailability. The compound has also shown potential as an antimycobacterial agent. Its multiple biological activities make it a valuable compound for therapeutic development.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 5-fluoroisatin typically evaluate its activity against various kinases and enzymes. A standard assay protocol involves incubating the compound with purified enzymes or receptors in appropriate buffer systems. The compound is dissolved in DMSO and diluted to working concentrations (typically 0.1 nM to 100 μM). Enzyme activity is measured by quantifying substrate conversion using colorimetric, fluorometric, or radiometric methods. Binding affinity is assessed using surface plasmon resonance or fluorescence polarization. IC₅₀ or Kd values are calculated from dose-response curves. The compound's isatin scaffold allows for interaction with multiple biological targets.
|
| Cell Assay |
Cellular assays for 5-fluoroisatin typically evaluate its anticancer, antibacterial, or antifungal activity. A standard protocol for anticancer activity involves culturing cancer cell lines (e.g., renal cell carcinoma, GIST cell lines) in growth medium at 37°C with 5% CO₂. Cells are treated with varying concentrations of the compound for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or SRB assays. Apoptosis and cell cycle analysis are performed using flow cytometry. For antimicrobial activity, bacterial or fungal cultures are treated with the compound and MIC values are determined. IC₅₀ or MIC values are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for 5-fluoroisatin are well-established due to its FDA approval for cancer treatment. Preclinical studies typically involve administering the compound to tumor-bearing mice via oral gavage or intravenous injection at doses determined from pharmacokinetic studies. Tumor volume and body weight are monitored regularly. Endpoints include tumor growth inhibition, survival analysis, and histopathological examination of tumor tissues. Pharmacokinetic parameters such as half-life, volume of distribution, and bioavailability are assessed. The compound's efficacy and safety profile have been established through extensive preclinical and clinical studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 5-fluoroisatin is well-characterized due to its FDA approval. The compound has a molecular weight of 165.12 g/mol and a molecular formula of C₈H₄FNO₂. It is a solid at room temperature. The fluorine substituent enhances the compound's metabolic stability and oral bioavailability. The compound is absorbed after oral administration and distributed to target tissues. It is metabolized primarily in the liver and excreted in urine and feces. Specific pharmacokinetic parameters are available from the published literature and drug labels. The compound's FDA approval for RCC and GIST confirms its favorable pharmacokinetic and safety profile.
|
| Toxicity/Toxicokinetics |
5-Fluoroisatin has been approved by the FDA for the treatment of renal cell carcinoma and gastrointestinal stromal tumor. The compound's safety profile has been established through clinical trials. Common adverse effects are consistent with other anticancer agents and may include gastrointestinal disturbances, fatigue, and hematological effects. The compound is classified as a therapeutic agent for specific indications. Standard safety precautions for handling include appropriate personal protective equipment. The compound should be stored in a dry, cool place away from incompatible materials. Detailed toxicological information is available from the drug label and published literature.
|
| Additional Infomation |
5-Fluoroin is an indole compound that has anti-coronavirus activity.
5-Fluoroisatin (5-Fluoro-1H-indole-2,3-dione, CAS 443-69-6) is a biochemical reagent and FDA-approved therapeutic agent with the molecular formula C₈H₄FNO₂. It is approved for the treatment of renal cell carcinoma and gastrointestinal stromal tumor. The compound has also shown antibacterial, antifungal, and antimycobacterial activities. It is classified as a research-use compound and as a therapeutic agent for specific indications. It is available from multiple commercial suppliers and pharmaceutical manufacturers. Clinical trials and FDA approval have been obtained for its use in cancer treatment. |
| Molecular Formula |
C8H4FNO2
|
|---|---|
| Molecular Weight |
165.12
|
| Exact Mass |
165.022
|
| CAS # |
443-69-6
|
| PubChem CID |
236566
|
| Appearance |
Solid Powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
417.9ºC at 760mmHg
|
| Melting Point |
224-227 °C(lit.)
|
| Flash Point |
206.5ºC
|
| Index of Refraction |
1.584
|
| LogP |
0.61
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
241
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1C([H])=C([H])C2=C(C=1[H])C(C(N2[H])=O)=O
|
| InChi Key |
GKODDAXOSGGARJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H4FNO2/c9-4-1-2-6-5(3-4)7(11)8(12)10-6/h1-3H,(H,10,11,12)
|
| Chemical Name |
5-fluoro-1H-indole-2,3-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0562 mL | 30.2810 mL | 60.5620 mL | |
| 5 mM | 1.2112 mL | 6.0562 mL | 12.1124 mL | |
| 10 mM | 0.6056 mL | 3.0281 mL | 6.0562 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
